Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.

Abstract

Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare infiltrative vascular tumors. Currently, no standard treatment regimens exist for KHE/TA. The purpose of our study was to evaluate the efficacy and safety of topical application of tacrolimus for superficial KHE/TA. We examined six patients with superficial KHE/TA. All patients were treated with tacrolimus 0.1% ointment twice daily for at least 12 months. The response rate was 100%, including three nearly complete remissions. Only one patient experienced local pruritus during treatment. The data constituted an intriguing rationale for clinical trials of topical tacrolimus in the treatment of superficial KHE/TA.

• Authors: Xuepeng Zhang, Kaiying Yang, Siyuan Chen, Yi Ji
• Journal: The Journal of dermatology (J Dermatol) Vol. 46 Issue 10 Pg. 898-901 (Oct 2019) ISSN: 1346-8138 [Electronic] England
• PMID: 31373046 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2019 Japanese Dermatological Association.

Chemical References

• Ointments
• Tacrolimus

Topics

• Administration, Cutaneous
• Biopsy
• Child, Preschool
• Female
• Hemangioendothelioma (diagnostic imaging, drug therapy, pathology)
• Hemangioma (diagnostic imaging, drug therapy, pathology)
• Humans
• Infant
• Kasabach-Merritt Syndrome (diagnostic imaging, drug therapy, pathology)
• Male
• Off-Label Use
• Ointments
• Photography
• Pruritus (chemically induced)
• Sarcoma, Kaposi (diagnostic imaging, drug therapy, pathology)
• Skin (diagnostic imaging, drug effects, pathology)
• Skin Neoplasms (diagnostic imaging, drug therapy, pathology)
• Tacrolimus (administration & dosage, adverse effects)
• Treatment Outcome